Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, Large B-Cell, Diffuse: early-phase trial registry
3 of 11 indexed Lymphoma, Large B-Cell, Diffuse trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Lymphoma, Large B-Cell, Diffuse: 11 US clinical trials tracked, 3 recruiting.
Lymphoma, Large B-Cell, Diffuse is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, running 2 of these trials.
Enrollment posture brief
Registry condition lymphoma-large-b-cell-diffuse
OPEN 3 | RECR 27% | LATE 0 | EARLY 11 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
Lymphoma, Large B-Cell, Diffuse lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, Large B-Cell, Diffuse on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, Large B-Cell, Diffuse is recruiting below its size-band peers.
3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphoma, Large B-Cell, Diffuse research.
Seagen accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoma, Large B-Cell, Diffuse enrolment sits around 64 participants.
Median target enrolment is 64 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.
-
Lymphoma, Large B-Cell, Diffuse research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Merck Sharp & Dohme
NCT06890884
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development
NCT05421663
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Jennifer Crombie, MD
NCT05800366
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06254495
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02208037
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT01421524
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01307267
A Safety Study of SGN-CD19A for B-Cell Lymphoma
Seagen
NCT01786135
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
NCT00849147
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen
NCT00655837
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Triphase Research and Development III
NCT03682796
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, Large B-Cell, Diffuse records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, Large B-Cell, Diffuse trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, Large B-Cell, Diffuse page
11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Lymphoma, Large B-Cell, Diffuse trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen sponsors the most Lymphoma, Large B-Cell, Diffuse trials on record, review their full trial history before evaluating a specific study. See Seagen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Large B-Cell, Diffuse condition card totals 11 registered trials; most-linked intervention rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.